Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Have proved their worth and now deserve a firmer foundation
| The first 150 words of the full text of this article appear below. |
Allogeneic stem cell transplantation has revolutionised the outcome for a wide range of malignant and non-malignant haematological conditions.1 Of the sources of stem cells, umbilical cord blood, obtained from the placenta directly after delivery, is enriched in stem cells and has a higher proliferative capacity than cells obtained from bone marrow and peripheral blood. 2 3 Like any blood product, however, stem cells from cord blood need an infrastructure for collecting, banking, and matching the donations.
Several cord blood banks and registries have been formed internationally (four of them in the United Kingdom) which collect the cord blood products and perform cryopreservation, tissue typing, and viral assessment. These products can then be accessed after a search of the internet linked databases and the cryopreserved product transported to the transplant centre for use.
Marrow engraftment can occur quite quickly after infusion of cord
blood, although it may be delayed in some instances
this
Read all Rapid Responses